Benzinga | Aug 24, 2021 08:23AM EDT

JP Morgan Initiates Coverage On RxSight with Overweight Rating, Announces Price Target of $16

JP Morgan analyst Robbie Marcus initiates coverage on RxSight (NASDAQ:RXST) with a Overweight rating and announces Price Target of $16.